Sunitinib malate and Plavix drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sunitinib malate (sunitinib malate) and Plavix (clopidogrel bisulfate). Common drug interactions include general physical health deterioration among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Sunitinib malate and Plavix. It is created by eHealthMe based on reports of 82 people who take the same drugs from the FDA, and is updated regularly.

What is Sunitinib malate?

Sunitinib malate has active ingredients of sunitinib malate. eHealthMe is studying from 9,160 Sunitinib malate users. Check the latest studies of Sunitinib malate.

What is Plavix?

Plavix has active ingredients of clopidogrel bisulfate. It is often used in stent. eHealthMe is studying from 151,179 Plavix users. Check the latest studies of Plavix.



On Aug, 03, 2026

82 people who take Sunitinib malate and Plavix together, and have interactions are studied.

Sunitinib malate and Plavix drug interactions.

What are the common drug interactions of Sunitinib Malate and Plavix, by gender? *:

female:

  1. General physical health deterioration (weak health status)
  2. Platelet count decreased
  3. Asthenia (weakness)
  4. Bronchial obstruction (blockage of the breathing passages to the lungs)
  5. Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
  6. Respiratory failure (inadequate gas exchange by the respiratory system)
  7. Abdominal pain upper
  8. Decreased appetite
  9. Diarrhoea
  10. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

male:

  1. Nausea (feeling of having an urge to vomit)
  2. Dyspnoea (difficult or laboured respiration)
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  4. Myxoedema (a disease caused by decreased activity of the thyroid gland in adults and characterized by dry skin, swellings)
  5. Neutropenia (an abnormally low number of neutrophils)
  6. Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
  7. Pancreatitis acute (sudden inflammation of pancreas)
  8. Performance status decreased
  9. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  10. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

What are the common drug interactions of Sunitinib Malate and Plavix, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Fall
  2. Gingival bleeding (bleeding gums)
  3. Soft tissue necrosis (death of soft tissue)
  4. Weight increased

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Myxoedema (a disease caused by decreased activity of the thyroid gland in adults and characterized by dry skin, swellings)
  2. Nausea (feeling of having an urge to vomit)
  3. Neoplasm progression (growth of tumour)
  4. Neutropenia (an abnormally low number of neutrophils)
  5. Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
  6. Pancreatitis acute (sudden inflammation of pancreas)
  7. Performance status decreased
  8. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  9. Abdominal pain
  10. Anxiety

60+:

  1. Death
  2. Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
  3. Cardiac arrest
  4. Localised oedema (fluid retention in a particular part of the body)
  5. Swollen tongue (swelling of tongue)
  6. Decreased appetite
  7. Diarrhoea
  8. General physical health deterioration (weak health status)
  9. Platelet count decreased
  10. Bronchial obstruction (blockage of the breathing passages to the lungs)

What are the existing conditions these people have? *

  1. High Blood Pressure: 40 people, 48.78%
  2. Prostate Cancer: 25 people, 30.49%
  3. High Blood Cholesterol: 15 people, 18.29%
  4. Pain: 15 people, 18.29%
  5. Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 13 people, 15.85%
  6. Constipation: 13 people, 15.85%
  7. Renal Cell Carcinoma (a kidney cancer): 12 people, 14.63%
  8. Diabetes: 11 people, 13.41%
  9. Nausea (feeling of having an urge to vomit): 11 people, 13.41%
  10. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 8 people, 9.76%

* Approximation only. Some reports may have incomplete information.

Do you take Sunitinib malate and Plavix?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sunitinib malate and Plavix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sunitinib malate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Plavix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sunitinib malate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Plavix and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sunitinib malate and clopidogrel bisulfate (the active ingredients of Sunitinib malate and Plavix, respectively), and Sunitinib malate and Plavix (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: